BIRMINGHAM, Ala., Sept. 16, 2026 (GLOBE NEWSWIRE) — Diversified Energy Company (NYSE:DEC; LSE:DEC) announced on May 6, 2026, a dividend in respect of the first quarter ended March 31, 2026, in the amount of 29 cents per share (the “Q1 2026 Dividend”).  The Company will pay the Q1 2026 Dividend on September 30, 2026, to those shareholders on the register on August 28, 2026. 

The Company announces that shareholders who have elected to receive their dividends in GBP sterling will receive an equivalent dividend payment of 21.567 pence per share, based on the September 10, 2026 exchange rate of GBP 0.73781 =US $1.00.

For further information, please contact:

Diversified Energy Company +1 973 856 2757
Doug Kris dkris@dgoc.com
Senior Vice President, Investor Relations & Corporate Communications www.div.energy
   
FTI Consulting dec@fticonsulting.com
U.S. & UK Financial Public Relations  

About Diversified Energy Company

Diversified is a leading publicly traded energy company focused on acquiring, operating, and optimizing cash generating energy assets. Through our unique differentiated strategy, we acquire existing, long-life assets and invest in them to improve environmental and operational performance until retiring those assets in a safe and environmentally secure manner. Recognized by ratings agencies and organizations for our sustainability leadership, this solutions-oriented, stewardship approach makes Diversified the Right Company at the Right Time to responsibly produce energy, deliver reliable free cash flow, and generate shareholder value.

ICG Enterprise Trust plc (the “Company”)

16 September 2026

Transaction in Own Shares

The Company announces that on 15 September 2026 it bought back 5,549 of its own shares under the long-term buyback programme, to be held as treasury shares, at an average price of 1400 pence per share.

Further details are set out below:

  • Number of shares held as treasury shares following settlement of this purchase: 3,179,951
  • Total shares in issue excluding treasury shares following settlement of this purchase: 60,374,241

The Company has bought back these shares under the authority granted by shareholders at its Annual General Meeting in June 2026, which permits the Company to repurchase a maximum of 14.99% of its ordinary shares. The actual number of shares repurchased by the Company will depend on market conditions. This authority lasts until the next shareholder authority granted (expected to be at the Annual General Meeting in 2027), or until expressly revoked by shareholders.

No maximum consideration payable has been determined by the Company, but the Company is unable to pay a price for any shares pursuant to the buyback which would equate to a premium to the net asset value. It is the Company’s current intention to hold any shares bought back in treasury.

The Company has instructed Numis Securities Limited (trading for these purposes as Deutsche Numis) as its broker in respect of its buyback transactions. This arrangement is in accordance with the UKLA Listing Rules and the Company’s general authority to repurchase shares.

Analyst / Investor enquiries:

Chris Hunt
Shareholder Relations, ICG
+44 (0) 20 3545 2020

Andrew Lewis
Company Secretary, ICG
+44 (0) 20 3545 1344

Media:

Clare Glynn
Corporate Communications, ICG
+44 (0) 20 3545 1395

Lochem, 16 September 2026

ForFarmers expands operations in Poland with acquisition of STW SA

ForFarmers, through its Polish subsidiary Tasomix, has entered into an agreement to acquire 100% of the shares in STW SA, an animal feed producer based in Sokołów Podlaski (eastern Poland). The transaction is in line with the growth strategy of ForFarmers to further strengthen their position in the Polish market, particularly in the poultry, ruminant and swine sectors. The acquisition is subject to approval by the Polish competition authority. The transaction is expected to be finalized at the beginning of 2027.

STW SA: modern feed production site
STW SA was founded in 2016 and is owned by the Leszczyński family. The company operates a modern feed production facility in Eastern Poland and is also active in feed logistics and poultry farming. Following recent investments, the annual feed production capacity has increased to approximately 270,000 tonnes. With a workforce of 76 employees, STW SA has developed substantial expertise and technical know-how in feed formulation.

Stronger position in an attractive growth market
Tasomix, which has been operating in Poland for over 35 years and has been part of ForFarmers since 2018, has been collaborating with STW SA for several years. As part of this partnership, STW SA already manufactures for Tasomix. 

“This acquisition, in which we are acquiring the production site and the product and customer portfolio, is a good addition to Tasomix’s activities in eastern Poland and creates scope for further growth. In addition, we will benefit from STW SA’s knowledge and experience and realise efficiency gains in production and logistics. This will enable us to serve our customers even better and further strengthen our position in the Polish market,” says Paweł Świerkula, Managing Director of Tasomix.

Michał Leszczyński, CEO of STW SA: “We are convinced that this acquisition lays a strong foundation for further growth and development. The combination of local commitment with the scale, knowledge and expertise of ForFarmers/Tasomix creates new opportunities for customers and employees. We look forward to working together to make this next step a success.”

Scope of the transaction
The transaction comprises the feed business with its modern production facility, excluding the feed logistics and poultry farming of the Leszczyński family.  Tasomix and  Leszczyński family intend to further strengthen their cooperation, particularly in the areas of logistics and the supply of feed to the poultry farms of the Leszczyński family.

This press release contains information that qualifies as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.

Note to the editor:
Media: Ilse Niehof-Duivelshof, T: +31 (0)573 28 88 00
Investors: Floor van Maaren, T +31 (0)573 28 88 00

Company profile
ForFarmers N.V. (ForFarmers) is a leading player in Europe, offering complete feed solutions for (organic) livestock farming and with annual sales of over 10 million tonnes of animal feed. With its mission statement ‘For the Future of Farming’, ForFarmers is committed to future-proof farming and making the agricultural sector even more sustainable. The company has production operations in the Netherlands (where the head office is located), Germany, Poland and the United Kingdom, and exports to various countries within and outside Europe. ForFarmers employs around 3,000 people and is listed on Euronext Amsterdam.

ForFarmers N.V., PO-Box 91, 7240 AB Lochem
T: +31 (0)573 28 88 00 – info@forfarmers.eu – www.forfarmersgroup.eu/en

FORWARD-LOOKING STATEMENTS

This document contains forward-looking statements that include ForFarmers’ regulatory capital and liquidity positions under certain specified scenarios. In addition, forward-looking statements may include, without limitation, statements containing words such as ”intends”, ”expects”, ”takes into account”, ”aims at”, ”has the plan”, ”estimates” and words of similar purport. These statements concern or may affect future matters, such as ForFarmers’ future financial results, business plans and current strategies. Forward-looking statements are subject to a number of risks and uncertainties that could cause actual results and performance to differ materially from the expected future results or performance implicitly or explicitly contained in forward-looking statements. Factors that may cause, or contribute to, differences in current expectations include, but are not limited to: developments in legislation, technology, taxation, case law and regulations, fluctuations in stock prices, legal proceedings, investigations by regulators, competitive conditions, and general economic conditions. These and other factors, risks and uncertainties that may affect any forward-looking statement or the actual results of ForFarmers are discussed in the latest published annual report. The forward-looking statements contained in this document relate solely to statements as of the date of this document, and ForFarmers assumes no obligation or responsibility to update the forward-looking statements contained in this announcement, whether in connection with new information, future events or otherwise, unless ForFarmers is required by law to do so.

Company presentation

BW Offshore is presenting today at Pareto Securities’ annual Energy Conference. Please see the attached presentation.

For further information, please contact:
Ståle Andreassen, CFO, +47 91 71 86 55
IR@bwoffshore.com   www.bwoffshore.com

About BW Offshore:

BW Offshore engineers innovative floating production solutions. The Company has a fleet of FPSOs and floating wind solutions. By leveraging four decades of offshore operations and project execution, the Company creates tailored offshore energy solutions for evolving markets worldwide. BW Offshore has around 900 employees and is publicly listed on the Oslo stock exchange.

This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act

Attachment

Press Release
Data on Nicox’s NCX 470 to be presented at AAOpt Annual Meeting 2026
September 16, 2026 – release at 7:30 am
Sophia Antipolis, France

Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that key scientific data on NCX 470 will be presented at the upcoming American Academy of Optometry (AAOpt) Annual Meeting 2026 (September 30 – October 3, 2026, Anaheim, CA, U.S.). Nicox will also be participating in several key ophthalmology, financial and industry conferences in the second half of 2026.

“NCX 470 is an investigational new drug for the reduction of intraocular pressure which has recently completed a multi-region Phase 3 clinical program. AAOpt provides an important opportunity to share the data from these trials directly with the optometrist community, which plays a central role in the diagnosis and ongoing management of glaucoma. This forum enables us to engage directly with optometrists and place the clinical findings for NCX 470 in the context of glaucoma management in everyday practice.” said Siobhan Garbutt, VP and Head of Clinical Development of Nicox.

Data from Nicox’s clinical trials, Denali, Whistler and Mont Blanc has already been presented at a number of key ophthalmology conferences. All publications can be found on our website.

AAOpt 2026 Annual Meeting – September 30 to October 3, 2026, Anaheim, CA, U.S. 

Presentation Details

 

Title: The Denali Trial U.S. Subgroup: A Randomized Trial Comparing NCX 470 0.1% and Latanoprost 0.005% for Open-Angle Glaucoma or Ocular Hypertension
Type: Paper Presentation
Date: Thursday, October 1, 2026 at 08:15 am (local time)
Presenter: Nora Cothran, OD, Fellow of the American Academy of Optometry

Title: Aqueous Humor Dynamics of NCX 470 Ophthalmic Solution (Nitric Oxide-Donating Bimatoprost): A Double-Masked, Placebo-Controlled, Phase 3b Clinical Trial

Type: Poster Presentation – Board #162
Date: Thursday, October 1, 2026 at 4:30 pm (local time)
Presenter: Siobhan Garbutt, PhD

H2 Conference Attendance

  • American Academy of Ophthalmology (AAO) – October 9-12, 2026 – New Orleans, Louisiana – United-States
  • Investor Access – October 6-7, 2026 – Paris, France

Members of the Nicox team will be available for one-on-one meetings at these events. If you wish to set up a meeting, please contact us at communications@nicox.com.

About NCX 470
NCX 470 is a novel nitric oxide (NO)-donating bimatoprost eye drop that leverages the potent intraocular pressure (IOP)-lowering effects of NO and prostaglandin analogs (PGAs). NCX 470 incorporates Nicox’s proprietary NO-donating research platform and bimatoprost in a single molecule. NCX 470 is designed to release bimatoprost and NO into the eye to lower IOP by two different pathways in patients with open-angle glaucoma or ocular hypertension. NO is a well-known small, naturally occurring signalling molecule that plays a key role in the regulation of IOP through activation of soluble guanylate cyclase (sGC). NO brings additional IOP-lowering efficacy by enhancing aqueous humor drainage from the eye via a different mechanism of action to that of PGAs.

NCX 470 has completed two Phase 3 clinical trials designed to fulfil the regulatory requirements for safety and efficacy to support NDA submissions in the U.S. and China, Mont Blanc and Denali. Both trials were positive and met the efficacy endpoints necessary for submission of a New Drug Application in the United States and China. NDAs for NCX 470 have been submitted in the U.S. and China. NCX 470 is an investigational product and has not yet been approved by the FDA.

About Nicox
Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health.  Nicox’s lead late-stage development program is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, licensed to Ocumension Therapeutics for the Chinese, Korean and Southeast Asian markets and to Kowa in the rest of the world.  Nicox also has a preclinical research program on NCX 1728, a nitric oxide-donating phosphodiesterase-5 inhibitor, with Glaukos.  Nicox’s first product, VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, is available commercially in the U.S. and over 15 other territories.  Nicox generates revenue from ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow, Inc. in the U.S., and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets.

Nicox, headquartered in Sophia Antipolis, France, is listed on Euronext Growth Paris (Ticker symbol: ALCOX).

For more information www.nicox.com

Analyst coverage

H.C. Wainwright & Co        Yi Chen           New York, U.S.

 
The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports.

Contacts  
Nicox
Gavin Spencer
Chief Executive Officer
T +33 (0)4 97 24 53 00
communications@nicox.com
 
Disclaimer
The information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.

Risks factors which are likely to have a material effect on Nicox’s business are presented in section 3 of the “Rapport Annuel 2024” and in section 4 of the “Rapport semestriel 2025” which are available on Nicox’s website (www.nicox.com).

Finally, this press release may be drafted in the French and English languages. If both versions are interpreted differently, the French language version shall prevail.

Nicox S.A.
Sundesk Sophia Antipolis, Bâtiment C, Emerald Square, Rue Evariste Galois, 06410 Biot, France
T +33 (0)4 97 24 53 00

Attachment

EfTEN United Property Fund earned a net profit of 58 thousand euros in August and 624 thousand euros over the first eight months of 2026 (2 012 thousand euros in the same period last year). The net asset value (NAV) of the fund unit was 11.58 euros at the end of August, increasing 0.2% over the month.

The lower-than-usual profit was primarily related to the fund’s investment in the shares of EfTEN Real Estate Fund AS, the price of which fell by 1.8% on the Tallinn Stock Exchange in August 2026. If the fund’s investment in the shares of EfTEN Real Estate Fund AS were recognised on the basis of its net asset value, EfTEN United Property Fund would have earned 163 thousand euros of profit in August and the fund’s NAV would be 11.66 euros, increasing 0.6% over the month.

In August, the fund acquired a 5.9% holding in EfTEN Domina SIA, which owns the Domina shopping centre in Riga. The acquisition cost of the fund’s investment was 2,478 thousand euros, and in August the fund earned 31 thousand euros of profit from the change in the fair value of the holding.

In August, the fund also acquired an 80% holding in its subsidiary Invego Uus-Järveküla 2 OÜ, which is developing the expansion of the Uus-Järveküla residential district. The detailed plan for the expansion is in its final phase. The fund earns 10% annual interest income on the 700 thousand euro shareholder loan granted to the company at the end of July.

No new sales agreements were concluded in August in the development company Invego Uus-Järveküla OÜ, in which the fund holds an 80% stake. Three terraced-houses and two land plots remain unsold in the development project.

A more detailed overview of EfTEN United Property Fund’s portfolio can be found on the fund’s website: https://eftenunitedpropertyfund.ee/en/fund-results-2/

Kristjan Tamla
Managing Director
Phone: 655 9515

E-mail: kristjan.tamla@eften.ee

Attachment

VALLOUREC SECURES A MAJOR CONTRACT WITH SUBSEA7 FOR PETROBRAS’ SEPIA 2 OFFSHORE PROJECT IN BRAZIL

Meudon, on September 16, 2026 – Vallourec, a world leader in premium seamless tubular solutions, announces that it has been awarded a major contract by Subsea7 for the supply of carbon steel seamless line pipe and thermal insulation coating for the Sepia 2 project, developed by Petrobras in the pre-salt Santos Basin, offshore Brazil.

This award follows the EPCI (Engineering, Procurement, Construction and Installation) contract recently secured by Subsea7 from Petrobras for the Sepia 2 project. Vallourec has secured the project’s entire carbon steel line pipe and external coating supply scope through a single integrated offer.

Under this contract, Vallourec will supply approximately 130 kilometers of rigid risers and flowlines, representing more than 15,000 tons of sour service carbon steel line pipe. The pipes will be produced at Vallourec’s Jeceaba mill in Minas Gerais, Brazil, with the related thermal insulation coating applied at the Vallourec Coating Solutions plant in Serra, Espírito Santo.

The Sepia 2 project is located in ultra-deep waters of the Santos Basin, a pre-salt area approximately 280 kilometers from the Brazilian coast, and is developed by a consortium led by Petrobras. It comprises 15 wells, as well as an export pipeline connected to a new
Floating Production Storage and Offloading (FPSO) vessel, to be installed in a water depth of approximately 2,170 meters.

This success highlights Vallourec’s ability to meet the highly demanding thermal insulation requirements of the installation and operation phases in extreme deepwater conditions. Thanks to its advanced Syntactic Polypropylene solutions, Vallourec will stand alongside Subsea7 and Petrobras to meet these challenges throughout project execution.

Philippe Guillemot, Chairman of the Board of Directors and Chief Executive Officer of the Vallourec Group, commented: “This contract illustrates the strength of Vallourec’s integrated offering, combining premium seamless line pipe and advanced thermal insulation coating. It confirms our position as a partner of choice for the most demanding pre-salt developments and showcases the excellence of our fully integrated industrial footprint in Brazil, from our Jeceaba mill to our Serra coating plant. I thank Subsea7 and Petrobras for this new mark of confidence, which rewards the dedication of our teams.”

About Vallourec

Vallourec is a world leader in premium tubular solutions for the energy markets and for demanding industrial applications such as oil & gas wells in harsh environments, new generation power plants, challenging architectural projects, and high-performance mechanical equipment. Vallourec’s pioneering spirit and cutting-edge R&D open new technological frontiers. With close to 13,000 dedicated and passionate employees in more than 20 countries, Vallourec works hand- in-hand with its customers to offer more than just tubes: Vallourec delivers innovative, safe, competitive and smart tubular solutions, to make every project possible. Listed on Euronext in Paris (ISIN code: FR0013506730, Ticker VK), Vallourec is part of the CAC Mid 60, SBF 120 and Next 150 indices and is eligible for Deferred Settlement Service. In the United States, Vallourec has established a sponsored Level 1 American Depositary Receipt (ADR) program (ISIN code: US92023R4074, Ticker: VLOWY). Parity between ADR and a Vallourec ordinary share has been set at 5:1. 

For further information, please contact:

Investor relations:

Daniel Thomson
Tel: +44(0)75 91 83 74 05
daniel.thomson@vallourec.com

Individual shareholders:
Toll Free number (From France): 0 805 65 10 10 
actionnaires@vallourec.com

Press relations: Taddeo

Romain Grière
Tel: +33 (0) 7 86 53 17 29
Tel: + 1 718 421 8374
romain.griere@taddeo.fr

Nicolas Escoulan
Tel: +33 (0)6 42 19 14 74
nicolas.escoulan@taddeo.fr

Attachment

The Management Board of TextMagic AS (registry code: 16211377, hereinafter the Company) proposes this draft resolution of the shareholders with a view to adopting, without calling a meeting in accordance with Section 2991 of the Commercial Code, the resolution of the shareholders of the Company on approval of the decrease of the voluntary reserve capital. 

In order to optimize costs, the Management Board of the Company has decided to arrange for the resolution to be adopted without convening a meeting and hence not to organise a general meeting of shareholders. 

Draft resolution:

Reduction of the voluntary reserve capital

Proposal of the Supervisory Board and the Management Board, and draft resolution.

1. To reduce the voluntary reserve capital of the Company by EUR 1,722,000 and to make a distribution to the shareholders in accordance with this resolution.

2. The distribution to be made as a result of the reduction of the Company’s voluntary reserve capital shall amount to EUR 0.20 per share (EUR 1,722,000 in total).

3. The remaining balance of the voluntary reserve capital after the distribution shall be EUR 25,988,000.

4. The distribution shall be allocated among all shareholders in proportion to the number of shares held by each shareholder in accordance with clause 4.12 of the Company’s articles of association.

The list of shareholders entitled to receive the distribution resulting from the reduction of the voluntary reserve capital shall be determined as at the close of the business day on 08.10.2026 (record date) in the Nasdaq CSD Estonian settlement system. Accordingly, the ex-date for the change of rights attached to the shares shall be 07.10.2026. The distribution shall be made to the shareholders no later than 14.10.2026.

Procedure and instructions for voting

A shareholder may review all documents related to the draft resolution on Company’s investors’ website https://investor.textmagic.com/ and at the Company’s location at A. H. Tammsaare tee 56, Tallinn, Harju County during business days from 09:00 to 17:00.

Questions regarding draft resolution, voting and other organizational issues are to be submitted to the Company’s e-mail address investor@textmagic.biz no later than by 25.09.2026 at 17:00.

The list of shareholders entitled to vote is fixed seven days before the end of the voting, i.e., on 23.09.2026 at the end of the business day of the settlement system of Nasdaq CSD Estonia. Shareholders may vote on draft resolutions only either by electronic means or by submitting a paper vote as follows:

  1. the voting will be open from 10:00 on 16.09.2026 until 12:00 on 30.09.2026 (GMT +3);
  2. a blank voting ballot is available at https://investor.textmagic.com/ where it can be filled in and the completed document can be downloaded for signing;
  3. for electronic voting, a shareholder or its representative must fill in a blank voting ballot in accordance with the instructions therein, sign it electronically (using an ID card, digital ID or Mobile ID) and forward the electronically signed voting ballot to the e-mail address investor@textmagic.biz by the deadline specified in clause (i) above;
  4. for paper voting, a shareholder or its legal or authorized representative must fill in a blank voting ballot in accordance with the instructions therein, sign it on paper and send the scanned voting ballot to the e-mail address investor@textmagic.biz and the original voting ballot to the Company’s head office at A. H. Tammsaare tee 56, 11316 Tallinn, Harju County, so that it arrives no later than at 12:00 (GMT+3) on 30.09.2026;
  5. if a blank voting ballot is filled in by an authorized representative of a shareholder, the original of the relevant power of attorney in the form (in electronic form or on paper) and by the time specified in (iv) above must be delivered in addition to the voting ballot itself. A template of the power of attorney is available at https://investor.textmagic.com/;
  6. if a blank voting ballot is filled in by a foreign legal entity, an extract of the registration entry of the relevant foreign legal entity, in the form (in electronic form or on paper) and by the time specified in (iv) above, showing the persons entitled to represent the foreign legal person must be delivered in addition to the voting ballot itself (and the power of attorney, if applicable).

Pursuant to Section 2991(2) of the Commercial Code, if a shareholder does not state within the specified term whether the shareholder is for or against a resolution, the shareholder will be deemed to have voted against the resolution.

The Management Board will publish the voting results as a stock exchange announcement and on the Company’s website in accordance with Section 2991(6) of the Commercial Code.
 

The following annexes are attached to this draft resolution:

Annex 1 – a blank voting ballot 
Annex 2 – a template of power of attorney

For more information, please contact:

Priit Vaikmaa
TextMagic AS CEO
investor@textmagic.biz

Attachments

TGS’ presentation for the Pareto Securities Energy Conference 2026 can be downloaded from www.newsweb.no or TGS’ website www.tgs.com.

CEO Kristian Johansen will present today at 15:55 CEST.

For more information, visit TGS.com (http://www.tgs.com) or contact:

Bård Stenberg VP IR & Business Intelligence

Mobile: +47 992 45 235 investor@tgs.com

Attachment

Strategic shareholders commit A$7.1 million at a premium to market, the Company’s fourth consecutive equity raise priced at a premium, alongside A$3.75 million of non-dilutive R&D Tax Incentive pre-financing

SYDNEY, Sept. 16, 2026 (GLOBE NEWSWIRE) — Cambium Bio Limited (ASX: CMB) (“Cambium Bio” or the “Company”), a clinical-stage regenerative medicine company developing biologic therapies for ophthalmology, today announced that it has secured an A$10.85 million funding package to initiate its pivotal Phase 3 trial of Elate Ocular® in moderate to severe dry eye disease (“DED”). The package comprises A$7.1 million (US$5.0 million) in firm commitments from strategic shareholders through a placement priced at A$0.48 per share, a 4.3% premium to the last closing price, and an A$3.75 million secured facility that pre-finances the Company’s FY2027 Research and Development Tax Incentive refund.

Highlights

  • Strategic capital at a premium. A$7.1 million committed by strategic shareholders, extending a track record of raising capital at a premium.
  • Funding to initiate the pivotal trial. CAMOMILE-2 is a single 475-patient Phase 3 trial that the U.S. Food and Drug Administration (FDA) has confirmed is sufficient to support a Biologics License Application (BLA). Initiation is targeted for the fourth quarter of 2026.
  • A potential first-in-class biologic. Elate Ocular® is a biologic derived from human platelet lysate. To the Company’s knowledge, no biologic therapy has been approved for the treatment of dry eye disease, and Elate Ocular® has the potential to be the first. The program holds FDA Fast Track designation.
  • Clear path to registration. Topline data from the pivotal trial are targeted for late calendar 2027. Subject to the trial meeting its co-primary sign and symptom endpoints, the Company intends to file a BLA with the FDA in 2028.

Karolis Rosickas, Chief Executive Officer of Cambium Bio, said:

“Our strategic shareholders have once again backed Cambium Bio at a premium to market, and that support now gives us the funding to start the pivotal trial of Elate Ocular®. Dry eye disease still has no approved biologic therapy. With one pivotal trial agreed with the FDA, Fast Track designation and the funding in place to initiate that trial, our path is clear: topline data in late 2027 and a BLA filing in 2028.”

The placement is conditional on shareholder approval at the Company’s 2026 Annual General Meeting. Full details are in the Company’s ASX announcement dated 16 September 2026 at www.asx.com.au.

About Cambium Bio Limited

Cambium Bio Limited (ASX: CMB) is a Sydney-based clinical-stage regenerative medicine company developing biologics for ophthalmology and tissue repair from its proprietary human platelet lysate technology. Its lead product candidate, Elate Ocular®, is being developed for moderate to severe dry eye disease.

Contact

Karolis Rosickas, Chief Executive Officer
info@cambium.bio

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.